Synergistic activity of interleukin-17 and tumor necrosis factor-α enhances oxidative stress-mediated oligodendrocyte apoptosis: IL-17/TNF-α-mediated oligodendrocyte loss
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Th1 cytokine-induced loss of oligodendrocytes (OLs) is associated with axonal loss in CNS demyelinating diseases such as multiple sclerosis (MS)that contributes to neurological disabilities in affected individuals. Recent studies indicated that, in addition to Th1-phenotype cytokines including tumor necrosis factor (TNF)-α, Th17 phenotype cytokine, interleukin (IL)-17 also involved in the development of MS. In this study, we investigated the direct effect of IL-17 on the survival of OLs in the presence of TNF-α and individually in vitro settings. Our findings suggest that IL-17 alone, however, was not able to affect the survival of OLs, but it exacerbates the TNF-α-induced OL apoptosis as compared with individual TNF-α treatment. This effect of cytokines was ascribed to an inhibition of cell-survival mechanisms, co-localization of Bid/Bax proteins in the mitochondrial membrane and caspase 8 activation mediated release of apoptosis inducing factor from mitochondria in treated OLs. In addition, cytokine treatment disturbed the mitochondrial membrane potential in OLs with corresponding increase in the generation of reactive oxygen species, which were attenuated by N-acetyl cysteine treatment. In addition, combining of these cytokines induced cell-cycle arrest at G1/S phases in OL-like cells and inhibited the maturation of OL progenitor cells that was attenuated by peroxisome proliferator-activated receptor-γ/-β agonists. Collectively, these data provide initial evidence that IL-17 exacerbates TNF-α-induced OL loss and inhibits the differentiation of OL progenitor cells suggesting that antioxidant- or peroxisome proliferator-activated receptor agonist-based therapies have potential to limit CNS demyelination in MS or other related demyelinating disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265
Immunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
IL-17 family cytokines and the expanding diversity of effector T cell lineages
Weaver, C. T., Hatton, R. D., Mangan, P. R., & Harrington, L. E. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141557 · Cited by 1,842 · cited 2×
“IL-17 is a pro-inflammatory cytokine secreted by Th17 cells, which has been shown to play a critical role in autoimmune-mediated inflammation (Park et al. 2005; McKenzie et al. 2006; Bettelli et al. 2007; Weaver et al. 2007).”
BackgroundKebir, H., Kreymborg, K., Ifergan, I., Dodelet-Devillers, A., Cayrol, R., Bernard, M., Giuliani, F., Arbour, N., Becher, B., & Prat, A. (2007) · Nature Medicine · doi:10.1038/nm1651 · Cited by 1,759 · cited 1×
“Recent studies document that Th17 cells migrate preferentially across the blood–brain barrier and that secreted IL-17 participates in inflammation and lesion formation in MS brain (Kebir et al. 2007).”
BackgroundInterleukin-23 drives innate and T cell–mediated intestinal inflammation
Hue, S., Ahern, P., Buonocore, S., Kullberg, M. C., Cua, D. J., McKenzie, B. S., Powrie, F., & Maloy, K. J. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061099 · Cited by 823 · cited 2×
“…and TNF-a in immune cells (Jovanovic et al. 1998) and implicated not only in MS model, but also in other autoimmune disease models such as rheumatoid arthritis (Nakae et al. 2003), inflammatory bowel disease (Hue et al. 2006), psoriasis (Zheng et al. 2007), and uveitis (Amadi-Obi et al. 2007).”
BackgroundInduction of gadd45β by NF-κB downregulates pro-apoptotic JNK signalling
De Smaele, E., Zazzeroni, F., Papa, S., Nguyen, D. U., Jin, R., Jones, J., Cong, R., & Franzoso, G. (2001) · Nature · doi:10.1038/35104560 · Cited by 732 · cited 1×
“TNF-a-mediated activation of JNK1/2 has been implicated in cell death signaling and studies suggest that NFjB activation protects cells from apoptosis via inhibition of JNK1/2 (De Smaele et al. 2001; Tang et al. 2001).”
BackgroundInhibition of JNK activation through NF-κB target genes
Tang, G., Minemoto, Y., Dibling, B., Purcell, N. H., Li, Z., Karin, M., & Lin, A. (2001) · Nature · doi:10.1038/35104568 · Cited by 721
Offen, D., Gilgun-Sherki, Y., & Melamed, E. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0348-9 · Cited by 638 · cited 2×
“Pro-inflammatory cytokines are reported to transduce cellular signaling through ROS (as second messenger) under disease conditions (Koch et al. 2006) and ROS play a major role in MS pathogenesis as mediators of CNS demyelination and axonal damage (Gilgun-Sherki et al. 2004).”
BackgroundMultiple sclerosis: Remyelination of nascent lesions: Remyelination of nascent lesions
Prineas, J. W., Barnard, R. O., Kwon, E. E., Sharer, L. R., & Cho, E. ‐. (1993) · Annals of Neurology · doi:10.1002/ana.410330203 · Cited by 574 · cited 3×
“A typical feature of CNS demyelinating diseases such as multiple sclerosis (MS) is the recurrence of inflammatory attacks that lead to oligodendrocyte (OL) loss which causes axonal loss and subsequent neurological disabilities in affected individuals (Prineas et al. 1993).”
BackgroundCellular mechanisms of IL-17-induced blood-brain barrier disruption
Huppert, J., Closhen, D., Croxford, A., White, R., Kulig, P., Pietrowski, E., Bechmann, I., Becher, B., Luhmann, H. J., Waisman, A., et al. (2010) · The FASEB Journal · doi:10.1096/fj.09-141978 · Cited by 529 · cited 2×
“IL-17-induced ROS generation in endothelial cells have been implicated in the compromised blood brain barrier integrity in MS model (Huppert et al. 2009).”
Background
Cited by
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
Microenvironment Imbalance of Spinal Cord Injury
Fan, B., Wei, Z., Yao, X., Shi, G., Cheng, X., Zhou, X., Zhou, H., Ning, G., Kong, X., & Feng, S. (2018) · Cell Transplantation · doi:10.1177/0963689718755778 · Cited by 536
Basic biology and role of interleukin‐17 in immunity and inflammation
Zenobia, C., & Hajishengallis, G. (2015) · Periodontology 2000 · doi:10.1111/prd.12083 · Cited by 470
The role of IL-17 in CNS diseases
Waisman, A., Hauptmann, J., & Regen, T. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1402-7 · Cited by 340
Interleukin-17 in chronic inflammatory neurological diseases
Milovanovic, J., Arsenijevic, A., Stojanovic, B., Kanjevac, T., Arsenijevic, D., Radosavljevic, G., Milovanovic, M., & Arsenijevic, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00947 · Cited by 250
Metadata
- Authors
- Paintlia, M. K., Paintlia, A. S., Singh, A. K., & Singh, I.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2011-01-19
- Volume
- 116
- Issue
- 4
- Pages
- 508-521
- ISSN
- 0022-3042 (ISSN-L)
- OpenAlex
- W1524830810
- Cited by
- 108
- References
- 13
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synergistic activity of interleukin-17 and tumor necrosis factor-α enhances oxidative stress-mediated oligodendrocyte apoptosis: IL-17/TNF-α-mediated oligodendrocyte loss. https://app.cochat.ai/papers/10.1111/j.1471-4159.2010.07136.x
- The paper
- Paintlia, M. K., Paintlia, A. S., Singh, A. K., & Singh, I. (2011). Synergistic activity of interleukin-17 and tumor necrosis factor-α enhances oxidative stress-mediated oligodendrocyte apoptosis: IL-17/TNF-α-mediated oligodendrocyte loss. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2010.07136.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.